The Most Important Facts About AmerisourceBergen

By Chris Stiles • Saturday, June 10 12:03 • Permanent Link

Large-cap Health Care company AmerisourceBergen moved 1.0% Friday on a volume of 779,831, compared to its average of 1,220,193. In contrast, the S&P 500 index moved 0.0%.

AmerisourceBergen trades -5.95% away from its average analyst target price of $189.5 per share. The 14 analysts following the stock have set target prices ranging from $172.0 to $208.0, and on average have given AmerisourceBergen a rating of buy.

Anyone interested in buying ABC should be aware of the facts below:

AmerisourceBergen's current price is 3880.7% above its Graham number of $4.48, which implies that at its current valuation it does not offer a margin of safety
AmerisourceBergen has moved 25.9% over the last year, and the S&P 500 logged a change of 14.6%
Based on its trailing earnings per share of 7.79, AmerisourceBergen has a trailing 12 month Price to Earnings (P/E) ratio of 22.9 while the S&P 500 average is 15.97
ABC has a forward P/E ratio of 14.0 based on its forward 12 month price to earnings (EPS) of $12.71 per share
The company has a price to earnings growth (PEG) ratio of 1.87 — a number near or below 1 signifying that AmerisourceBergen is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 128.03 compared to its sector average of 4.16
AmerisourceBergen Corporation sources and distributes pharmaceutical products.
Based in Conshohocken, the company has 39,000 full time employees and a market cap of $36.03 Billion. AmerisourceBergen currently returns an annual dividend yield of 1.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.